• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by electroCore Inc.

    12/7/23 7:53:51 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ECOR alert in real time by email
    SC 13G 1 a3g_theofilos.htm INITIAL 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    electroCore, Inc.
    (Name of Issuer)
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
    28531P103
    (CUSIP Number)
    December 4, 2023
    (Date of Event Which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐
    Rule 13d-1(b)
    ☒
    Rule 13d-1(c)
    ☐
    Rule 13d-1(d)
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 28531P103
     

    1
    NAME OF REPORTING PERSON
     
    Charles Steve Theofilos, MD
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
    (a)  ☐
     
    (b)  ☐
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States of America
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
    5
    SOLE VOTING POWER
    326,437
    6
    SHARED VOTING POWER
    85,973
    7
    SOLE DISPOSITIVE POWER
    326,437
    8
    SHARED DISPOSITIVE POWER
    85,973
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    412,410
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.9% (2)
    12
    TYPE OF REPORTING PERSON (see instructions)
    IN

    (2) Based on 6,002,420 shares of Common Stock outstanding as of November 1, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on November 8, 2023.


    CUSIP No. 28531P103
     

    1
    NAME OF REPORTING PERSON
     
    Kathryn Theofilos
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
    (a)  ☐
     
    (b)  ☐
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States of America
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
    5
    SOLE VOTING POWER
    8,556
    6
    SHARED VOTING POWER
    629,377 (1)
    7
    SOLE DISPOSITIVE POWER
    8,556
    8
    SHARED DISPOSITIVE POWER
    629,377 (1)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    637,933 (1)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.9% (1)(2)
    12
    TYPE OF REPORTING PERSON (see instructions)
    IN

    (1) Includes (a) 85,973 shares of Common Stock held in a joint account with her spouse, Charles Theofilos, MD (b) 153,168 shares of Common Stock held by Happy Holstein, LLLP, a Florida limited liability limited partnership, of which Happy Holstein Management, LLC is the general partner, of which Kathryn Theofilos is the manager, (c) 790 shares of Common Stock held by MCKT, LLC, a Florida limited liability company of which Kathryn Theofilos is the manager, (d) 6,142 shares held by Kathy Theofilos’ adult children, over which she shares voting and dispositive power, (e) 113,114 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants (as described in Item 4 and subject to the limitations as described therein) held by Happy Holstein Management, LLC, and (f) 270,190 shares of Common Stock issuable upon the exercise of the Warrants (as described in Item 4 and subject to the limitations as described therein) held by Happy Holstein Management, LLC. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of the Prefunded Warrants and the Warrants held by Happy Holstein Management, LLC as a result of the beneficial ownership limitations set forth in the Prefunded Warrants and the Warrants, as described in Item 4.

    (2) Based on 6,002,420 shares of Common Stock outstanding as of November 1, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on November 8, 2023, plus 113,114 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants (as described in Item 4) and 270,190 shares of Common Stock issuable upon exercise of the Warrants (as described in Item 4) that are subject to the limitations on exercise described in Item 4.

    CUSIP No. 28531P103
     

    1
    NAME OF REPORTING PERSON
     
    Happy Holstein Management, LLC
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
    (a)  ☐
     
    (b)  ☐
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
    5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    536,472(1)
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    536,472(1)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    536,472(1)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    8.4% (1)(2)
    12
    TYPE OF REPORTING PERSON (see instructions)
    OO

    (1) Includes (a) 153,168 shares of Common Stock held by Happy Holstein, LLLP, a Florida limited liability limited partnership, of which Happy Holstein Management, LLC is the general partner, (b) 113,114 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants (as described in Item 4 and subject to the limitations as described therein) held by Happy Holstein Management, LLC, and (c) 270,190 shares of Common Stock issuable upon the exercise of the Warrants (as described in Item 4 and subject to the limitations as described therein) held by Happy Holstein Management, LLC. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of the Prefunded Warrants and the Warrants held by Happy Holstein Management, LLC as a result of the beneficial ownership limitations set forth in the Prefunded Warrants and the Warrants, as described in Item 4.

    (2) Based on 6,002,420 shares of Common Stock outstanding as of November 1, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on November 8, 2023, plus 113,114 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants (as described in Item 4) and 270,190 shares of Common Stock issuable upon exercise of the Warrants (as described in Item 4) that are subject to the limitations on exercise described in Item 4.



    Item 1(a).  Name of Issuer: electroCore, Inc. (the “Issuer”)
    Item 1(b).  Address of Issuer’s Principal Executive Offices: The Issuer’s principal executive offices are located at 200 Forge Way, Suite 205, Rockaway, NJ 07866.
    Item 2(a).  Names of Persons Filing:
    This Schedule 13G is being filed by: (i) Charles Steve Theofilos, MD; (ii) Kathryn Theofilos; and (iii) Happy Holstein Management, LLC, a Florida limited liability company (collectively, the "Reporting Persons"). Kathryn Theofilos serves as manager of Happy Holstein Management, LLC.
    Item 2(b).  Address of Principal Business Office or, if None, Residence:
    The principal business address for the Reporting Persons is 300 Village Square Crossing, Suite 102, Palm Beach Gardens, FL 33410.
    Item 2(c).  Citizenship:
    See responses on Item 4 on the cover page of each Reporting Person.
    Item 2(d).  Title of Class of Securities: Common Stock, par value $0.001 per share.
    Item 2(e).  CUSIP Number: 28531P103

    Item 3.  If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
    (a)
    □
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     
    (b)
    □
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     
    (c)
    □
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     
    (d)
    □
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
    (e)
    □
    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
     
    (f)
    □
    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
     
    (g)
    □
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
     
    (h)
    □
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)
    □
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j)
    □
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
     
    (k)
    □
    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _________________.
    Not Applicable.


    Item 4.  Ownership.
    Please provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    The ownership information below is based upon 6,002,420 shares of Common Stock outstanding as of November 1, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on November 8, 2023, plus, for purposes of Kathryn Theofilos and Happy Holstein Management, LLC: (i) 113,114 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and (ii) 270,190 shares of Common Stock issuable upon exercise of the Warrants, each of which are subject to the limitations on exercise described below. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)

    Person
     
    Total Shares Of Common Stock Beneficially Owned
     
    Percent of Common Stock
     
    Sole Voting Power
     
    Shared Voting Power
     
    Sole Power to Dispose
     
    Shared Power to Dispose
    Charles Steve Theofilos, MD
     
    412,410 (1)
     
    6.9%
     
    326,437
     
    85,973
     
    326,437
     
    85,973
    Kathryn Theofilos
     
    637,933 (2)
     
    9.9%
     
    8,556
     
    629,377
     
    8,556
     
    629,377
    Happy Holstein Management, LLC
     
    536,472 (3)
     
    8.4%
     
    0
     
    536,472
     
    0
     
    536,472
    (1)   Includes (a) 326,437 shares of Common Stock held by Dr. Theofilos directly pursuant to a self-directed IRA, and (b) 85,973 shares of Common Stock held in a joint account with his spouse, Kathryn Theofilos.
    (2)   Includes (a) 85,973 shares of Common Stock held in a joint account with her spouse, Charles Theofilos, MD, (b) 153,168 shares of Common Stock held by Happy Holstein, LLLP, a Florida limited liability limited partnership, of which Happy Holstein Management, LLC is the general partner, of which Kathryn Theofilos is the manager, (c) 790 shares of Common Stock held by MCKT, LLC, a Florida limited liability company of which Kathryn Theofilos is the manager, (d) 6,142 shares held by Kathy Theofilos’ adult children, over which she shares voting and dispositive power, (e) 113,114 warrants to purchase shares of Common Stock that were issued on August 2, 2023 (the “Pre-funded Warrants”) that were immediately exercisable on a 1-for-1 basis into Common Stock at an exercise price of $0.001 per share, subject to the terms of the Pre-funded Warrants, held by Happy Holstein Management, LLC, and (f) 270,190 warrants to purchase shares of Common Stock that were issued on August 2, 2023 (the “Warrants”) that will become exercisable on February 2, 2024 on a 1-for-1 basis into Common Stock at an exercise price of $0.001 per share, subject to the terms of the Warrants held by Happy Holstein Management, LLC. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of the Prefunded Warrants and the Warrants held by Happy Holstein Management, LLC as a result of the beneficial ownership limitations set forth in the Prefunded Warrants and the Warrants, as described below in this footnote (2).
    Subject to the Pre-Funded Warrant Beneficial Ownership Limitation described in the following sentence, the Pre-Funded Warrants are exercisable at any time by delivery of notice to the Issuer, and permit the holder to purchase Common Stock for $0.001 per share (as adjusted from time to time, as provided in the Pre-Funded Warrants). The Pre-Funded Warrants may not be exercised if the holder, together with its affiliates and any persons who are members of a Section 13(d) group with the holders, would beneficially own more than a designated percentage (the “Pre-Funded Warrant Beneficial Ownership Limitation”), which currently is 9.99%, of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. A holder may increase or decrease the Pre-Funded Warrant Beneficial Ownership Limitation by written notice to the Issuer, provided that any such increase requires at least 61 days’ prior notice to the Issuer.
    Subject to the Warrant Beneficial Ownership Limitation described in the following sentence, the Warrants are exercisable at any time by delivery of notice to the Issuer, and permit the holder to purchase Common Stock for $0.001 per share (as adjusted from time to time, as provided in the Warrants). The Warrants may not be exercised if the holder, together with its affiliates and any persons who are members of a Section 13(d) group with the holders, would beneficially own more than a designated percentage (the “Warrant Beneficial Ownership Limitation”), which currently is 9.99%, of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. A holder may increase or decrease the Warrant Beneficial Ownership Limitation by written notice to the Issuer, provided that any such increase requires at least 61 days’ prior notice to the Issuer.
    (3)   Includes (a) 153,168 shares of Common Stock held by Happy Holstein, LLLP, a Florida limited liability limited partnership, of which Happy Holstein Management, LLC is the general partner, (b) 113,114 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants (as described in footnote (2) above and subject to the limitations as described therein) held by Happy Holstein Management, LLC, and (c) 270,190 shares of Common Stock issuable upon the exercise of the Warrants (as described in footnote (2) above and subject to the limitations as described therein) held by Happy Holstein Management, LLC. The share numbers in the preceding sentence represent the maximum number of shares of Common Stock issuable upon exercise of the Prefunded Warrants and the Warrants held by Happy Holstein Management, LLC as a result of the beneficial ownership limitations set forth in the Prefunded Warrants and the Warrants, as described in footnote (2).


    Item 5.  Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following □.
    Not applicable.
    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
    Not applicable.
    Item 8.  Identification and Classification of Members of the Group.
    Not Applicable.
    Item 9.  Notice of Dissolution of Group.
    Not Applicable.
    Item 10.  Certifications.
    The Reporting Persons hereby make the following certification:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: December 7, 2023
     
       
    Dr. Charles Theofilos
     
       
    /s/ Dr. Charles Theofilos
       
     
     
     
    Kathryn Theofilos
     
    /s/ Kathryn Theofilos
       
     
     
     
    Happy Holstein Management, LLC
     
    /s/ Kathryn Theofilos
       
    Name: Kathryn Theofilos
    Title: Manager




    LIST OF EXHIBITS

    Exhibit No.
     
    Description
    99.1
     
    Joint Filing Agreement, dated December 7, 2023, entered into by Dr. Charles Theofilos, Kathryn Theofilos and Happy Holstein Management, LLC.


    Get the next $ECOR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ECOR

    DatePrice TargetRatingAnalyst
    1/19/2022$3.00 → $2.75Buy
    HC Wainwright & Co.
    7/27/2021$3.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ECOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    electroCore Appoints Elena Bonfiglioli to Board of Directors

    ROCKAWAY, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore's Board of Directors, effective September 2, 2025. Ms. Bonfiglioli's appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications' solutions, responsible for go-to-market, commercial, and partnerships, enabling

    9/3/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore to Participate at H.C. Wainwright Global Investment Conference

    ROCKAWAY, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference. The conference will take place in New York on Tuesday, September 9, 2025 at the Lotte New York Palace Hotel. Management will host one-on-one meetings throughout the day. Investors who wish to request a meeting should contact their sales representative at H.C. Wainwright or reach out to electroCore Investor Relations at [email protected]. About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic technology compa

    9/2/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Names Kelly Benning, Accomplished Healthcare Executive, as SVP of Truvaga

    ROCKAWAY, N.J., Aug. 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Kelly Benning has been hired as the Senior Vice President of Truvaga, effective July 21, 2025. Ms. Benning, who brings almost three decades of leadership experience across digital health, AI-enabled technologies, and consumer wellness, will lead electroCore's consumer wellness division. Kelly Benning, electroCore's Senior Vice President of Truvaga "As an ever-increasing number of people are beginning to be more aware of the link between their lifestyle choices and well-being, wellness has evolved from a niche trend to a

    8/12/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on electroCore with a new price target

    HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously

    1/19/22 6:31:24 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ladenburg Thalmann initiated coverage on electroCore with a new price target

    Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00

    7/27/21 7:13:01 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Maxim Group resumed coverage on electroCore with a new price target

    Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00

    3/13/21 8:17:18 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Errico Thomas J. bought $67,050 worth of shares (15,000 units at $4.47), increasing direct ownership by 6% to 281,401 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    8/13/25 6:05:11 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Goldberger Daniel S bought $4,230 worth of shares (1,000 units at $4.23), increasing direct ownership by 0.34% to 291,565 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    8/12/25 6:05:12 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Gandolfo John P bought $9,018 worth of shares (1,800 units at $5.01), increasing direct ownership by 3% to 69,087 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    5/27/25 9:27:51 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Leadership Updates

    Live Leadership Updates

    View All

    electroCore Appoints Elena Bonfiglioli to Board of Directors

    ROCKAWAY, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore's Board of Directors, effective September 2, 2025. Ms. Bonfiglioli's appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications' solutions, responsible for go-to-market, commercial, and partnerships, enabling

    9/3/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Appoints James C. Theofilos to the Board of Directors

    ROCKAWAY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that James C. Theofilos has been appointed to the Board of Directors, effective August 1, 2025. "I'm honored to have been appointed to the Board of Directors at electroCore," said Mr. Theofilos. "For nearly two decades, the Theofilos family has deeply believed in the power of the vagus nerve and proudly supported electroCore as both an early investor and founding partner. At Microsoft, I've had the privilege of serving as the global finance lead for our healthcare and life sciences business — working alongside some of the worl

    8/5/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore to Join Russell Microcap® Index

    ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan

    6/11/24 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by electroCore Inc. (Amendment)

    SC 13D/A - electroCore, Inc. (0001560258) (Subject)

    6/7/24 4:33:08 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by electroCore Inc. (Amendment)

    SC 13G/A - electroCore, Inc. (0001560258) (Subject)

    2/14/24 3:15:55 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by electroCore Inc.

    SC 13D - electroCore, Inc. (0001560258) (Subject)

    12/18/23 4:10:26 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    SEC Filings

    View All

    electroCore Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - electroCore, Inc. (0001560258) (Filer)

    9/3/25 8:55:24 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by electroCore Inc.

    10-Q - electroCore, Inc. (0001560258) (Filer)

    8/6/25 4:21:08 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - electroCore, Inc. (0001560258) (Filer)

    8/6/25 4:11:01 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Errico Thomas J. bought $67,050 worth of shares (15,000 units at $4.47), increasing direct ownership by 6% to 281,401 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    8/13/25 6:05:11 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Goldberger Daniel S bought $4,230 worth of shares (1,000 units at $4.23), increasing direct ownership by 0.34% to 291,565 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    8/12/25 6:05:12 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Theofilos James Charles was granted 22,156 shares, increasing direct ownership by 1,593% to 23,547 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    8/5/25 4:31:30 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Financials

    Live finance-specific insights

    View All

    electroCore Announces Second Quarter 2025 Financial Results

    Net sales of $7.4 million increased 20% vs. Q2'2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025  Company to host a conference call and webcast today, August 6, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the three and six months ended June 30, 2025. Recent Highlights Record revenue for Q2'2025 of $7.4 million, a 20% increase over Q2'2024Year-to-Date revenue of $14.1 million, a

    8/6/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces First Quarter 2025 Financial Results

    First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. ("NeuroMetrix"); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights Reported first quarter 2025 revenue of $6.7 million, a 23% increase over first quarter 2024Revenue excluding TAC-STIM totaled $

    5/7/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces Full Year 2024 Financial Results

    Record full year 2024 net sales of $25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCoreTM in the United States Department of Veteran Affairs and United States Department of Defense (VA) and 174% increase in TruvagaTM sales Company to host a conference call and webcast today, March 12, 2025 at 5:30pm EDT ROCKAWAY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic medicine Company and wellness company, today announced fourth quarter and full year 2024 financial results. Recent Highlights Reported record full year of 2024 revenue of $25.2 m

    3/12/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ECOR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Stock Movement: Insider Purchase at electroCore Inc. on Jun 6

    **Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report

    6/10/24 12:57:57 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care